What is Zacks Small Cap’s Estimate for LEXX Q2 Earnings?

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Stock analysts at Zacks Small Cap issued their Q2 2025 earnings per share estimates for shares of Lexaria Bioscience in a research note issued to investors on Tuesday, January 28th. Zacks Small Cap analyst J. Vandermosten expects that the company will post earnings per share of ($0.14) for the quarter. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.42) per share. Zacks Small Cap also issued estimates for Lexaria Bioscience’s Q3 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.57) EPS and FY2026 earnings at ($0.45) EPS.

Separately, HC Wainwright decreased their price target on Lexaria Bioscience from $10.00 to $7.00 and set a “buy” rating for the company in a report on Friday, January 24th.

Lexaria Bioscience Price Performance

Lexaria Bioscience stock opened at $1.81 on Thursday. Lexaria Bioscience has a 52-week low of $1.43 and a 52-week high of $6.85. The firm has a fifty day moving average of $2.14 and a 200-day moving average of $2.71.

Lexaria Bioscience (NASDAQ:LEXX) last posted its earnings results on Friday, January 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). Lexaria Bioscience had a negative return on equity of 88.88% and a negative net margin of 1,473.04%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in LEXX. XTX Topco Ltd raised its stake in shares of Lexaria Bioscience by 47.8% in the 3rd quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock valued at $57,000 after purchasing an additional 6,024 shares in the last quarter. HighTower Advisors LLC acquired a new position in Lexaria Bioscience in the third quarter worth about $40,000. Geode Capital Management LLC increased its holdings in Lexaria Bioscience by 31.0% in the third quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock valued at $459,000 after buying an additional 35,608 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Lexaria Bioscience during the second quarter valued at approximately $63,000. Finally, Byrne Asset Management LLC grew its position in shares of Lexaria Bioscience by 132.1% in the 4th quarter. Byrne Asset Management LLC now owns 13,000 shares of the company’s stock worth $27,000 after acquiring an additional 7,400 shares in the last quarter. 13.06% of the stock is currently owned by institutional investors.

Insider Transactions at Lexaria Bioscience

In related news, CEO Richard Christopher purchased 22,828 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was acquired at an average price of $2.24 per share, for a total transaction of $51,134.72. Following the completion of the purchase, the chief executive officer now owns 22,828 shares in the company, valued at approximately $51,134.72. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 26.40% of the company’s stock.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.